Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced preliminary revenue results for the fourth quarter and full year 2021.
Preliminary, unaudited revenue for the fourth quarter 2021 is expected to be between $58 million and $60 million, reflecting growth of approximately 300% over the unaudited third quarter of 2021. Preliminary unaudited revenue for full year 2021, the first year of commercialization, is expected to be between $90 million and $92 million.
Based on sales pipeline visibility and manufacturing capacity, Lucira projects revenue for 2022 in excess of $450 million.
https://finance.yahoo.com/news/lucira-health-reports-preliminary-revenue-120000661.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.